Does a sphingosine kinase inhibitor induce cell death in temozolomide resistant glioblastoma cells?
Addition of a sphingosine kinase inhibitor to the standard chemotherapy regimen against GBM may be beneficial.
Donor MA exposure may be associated with increased Cr365 in recipients. Transplant centers can expect to encounter donors with MA use histories at rates higher that regional use rates. Larger studies may demonstrate MA exposure as an independent predictor of impaired graft function.